MYGN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

205.14M

-3.83%

-0.011

-118.97%

Estimates Revision

The market is revising Downward the revenue expectations for Myriad Genetics, Inc. (MYGN) for FY2025, with the revenue forecasts being adjusted by -0.05% over the past three months. During the same period, the stock price has changed by -15.70%.

Revenue Estimates for FY2025

Revise Downward

-0.05%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-16.86%

In Past 3 Month

Stock Price

Go Down

-15.70%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast MYGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MYGN is 8.50 USD with a low forecast of 8.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

2 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

8.00

Averages

8.50

High

9.00

Current: 0.000

Low

8.00

Averages

8.50

High

9.00

TD Cowen

Hold

downgrade

$9 -> $7

2026-01-07

New

Reason

TD Cowen

Price Target

$9 -> $7

2026-01-07

New

downgrade

Hold

Reason

TD Cowen lowered the firm's price target on Myriad Genetics to $7 from $9 and keeps a Hold rating on the shares. The firm adjusted targets in the diagnostics group as part of a Q4 preview. It expects solid results and 2026 outlooks for the sector, saying strong fundamentals remain.

Piper Sandler

Overweight

downgrade

2025-11-11

Reason

Piper Sandler

Price Target

2025-11-11

downgrade

Overweight

Reason

Piper Sandler lowered the firm's price target on Myriad Genetics to $8.50 from $9 and keeps an Overweight rating on the shares. The firm cites the company's quarterly results for the price target change.

UBS

Lu Li

Neutral

maintain

$6 -> $8

2025-11-04

Reason

UBS

Lu Li

Price Target

$6 -> $8

2025-11-04

maintain

Neutral

Reason

UBS analyst Lu Li raised the firm's price target on Myriad Genetics to $8 from $6 and keeps a Neutral rating on the shares.

TD Cowen

Hold

maintain

$8 -> $9

2025-11-04

Reason

TD Cowen

Price Target

$8 -> $9

2025-11-04

maintain

Hold

Reason

TD Cowen raised the firm's price target on Myriad Genetics to $9 from $8 and keeps a Hold rating on the shares. The firm said they reported a 3Q result about in line with consensus expectations, with HCT and GeneSight bright spots and Prenatal a bit weak but improving.

Scotiabank

Outperform -> Sector Perform

downgrade

$20 -> $6

2025-05-21

Reason

Scotiabank

Price Target

$20 -> $6

2025-05-21

downgrade

Outperform -> Sector Perform

Reason

As previously reported, Scotiabank downgraded Myriad Genetics to Sector Perform from Outperform with a price target of $6, down from $20. While the firm continues to believe there is opportunity for Myriad to execute against its Oncology and Women's Health business ambitions over the next several years, 2025 is likely to be "a transitional year," the analyst tells investors in a research note. The firm would like to see tangible and consistent progress and also waits for a potential strategy reset under the new CEO before turning more positive on shares, the analyst added.

BofA

Underperform

downgrade

$9 -> $4

2025-05-20

Reason

BofA

Price Target

$9 -> $4

2025-05-20

downgrade

Underperform

Reason

BofA lowered the firm's price target on Myriad Genetics to $4 from $9 and keeps an Underperform rating on the shares following what the firm says was "another disappointing quarter," headlined by a $35M reduction to sales guidance. Myriad has continued to experience headwinds and "the company has not managed to turn the page," says the analyst, who updated estimates accounting for continued headwinds and revised guidance.

Valuation Metrics

The current forward P/E ratio for Myriad Genetics Inc (MYGN.O) is 196.17, compared to its 5-year average forward P/E of -8.04. For a more detailed relative valuation and DCF analysis to assess Myriad Genetics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.04

Current PE

196.17

Overvalued PE

428.42

Undervalued PE

-444.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

39.17

Current EV/EBITDA

18.39

Overvalued EV/EBITDA

124.52

Undervalued EV/EBITDA

-46.18

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.25

Current PS

0.67

Overvalued PS

3.18

Undervalued PS

1.32

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

MYGN News & Events

Events Timeline

No data

News

1.0

01-05Globenewswire

Myriad Genetics CEO Sam Raha to Present at J.P. Morgan Healthcare Conference on Jan 14

3.5

2025-12-09Newsfilter

Myriad Genetics Presents Eight Breast Cancer Research Abstracts at SABCS 2025

4.5

2025-11-26Yahoo Finance

Market Update: Health Care Stocks Rise in Premarket Trading on Wednesday

People Also Watch

Frequently Asked Questions

What is Myriad Genetics Inc (MYGN) stock price today?

The current price of MYGN is 6.525 USD — it has decreased -0.53 % in the last trading day.

What is Myriad Genetics Inc (MYGN)'s business?

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.

What is the price predicton of MYGN Stock?

What is Myriad Genetics Inc (MYGN)'s revenue for the last quarter?

Myriad Genetics Inc revenue for the last quarter amounts to 205.70M USD, decreased -3.56 % YoY.

What is Myriad Genetics Inc (MYGN)'s earnings per share (EPS) for the last quarter?

Myriad Genetics Inc. EPS for the last quarter amounts to -0.29 USD, increased 20.83 % YoY.

What changes have occurred in the market's expectations for Myriad Genetics Inc (MYGN)'s fundamentals?

How many employees does Myriad Genetics Inc (MYGN). have?

Myriad Genetics Inc (MYGN) has 2700 emplpoyees as of January 09 2026.

What is Myriad Genetics Inc (MYGN) market cap?

Today MYGN has the market capitalization of 611.48M USD.